China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Britain Courts Anthropic Amid US Defense Department Dispute 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
 - EconoTimes)
NEW YORK, Sept. 08, 2016 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Medivation, Inc. (“Medivation” or the “Company”) (Nasdaq:MDVN) in the United States District Court for the Northern District of California on behalf of current stock holders of Medivation, seeking to pursue remedies under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that the $81.50 per share merger consideration via a tender offer by Montreal, Inc., a wholly-owned subsidiary of Pfizer Inc. (“Pfizer”), which was commenced on August 30, 2016 and is scheduled to expire on September 27, 2016 fails to provide Medivation shareholders with fair value for their shares. The Complaint also alleges that the inadequate merger consideration is the result of a rushed sale process during which the Board of Directors of Medivation caved to pressure from larger pharmaceutical companies that were eager to acquire Medivation at a discount to its intrinsic value and long-term prospects. Further, the Complaint alleges that in violation of Sections 14(e), 14(d)(4) and 20(a) of the Exchange Act, the tender offer documents omit certain material information, which renders the information disclosed materially misleading. Specifically, the Complaint alleges that the tender offer fails to disclose certain information about: (i) communications from other interested parties that were involved in negotiations to acquire Medivation; (ii) the terms of the confidentiality agreements entered into by such parties; and (iii) the valuation analyses performed by the Company’s financial advisors, J.P. Morgan Securities LLC (“J.P. Morgan”) and Evercore Group L.L.C. (“Evercore”).
If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
